OCCASIONAL VIEWPOINT

Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence

U Thalheimer, M Mela, D Patch, A K Burroughs

Recurrent variceal bleeding is very frequent after variceal haemorrhage and pharmacological therapy is the first choice treatment. Recently, baseline and repeat measurements of hepatic venous pressure gradient (HVPG) have been considered necessary to optimally manage patients receiving pharmacological therapy so as to reduce the frequency of rebleeding. However, the clinical validity and applicability of monitoring for target HVPG reductions is not sufficiently proven and needs to be specifically evaluated in a prospective trial.

SUMMARY

Recurrent variceal bleeding is very frequent after variceal haemorrhage unless secondary prevention with pharmacological or endoscopic therapy is used. Recently, baseline and repeat measurements of hepatic venous pressure gradient (HVPG) have been considered necessary to optimally manage patients receiving pharmacological therapy so as to reduce the frequency of rebleeding, by defining two targets: >20% reduction from baseline HVPG, and an absolute reduction to <12 mm Hg. Five key studies are identified which contain data related to this issue, which are different in their study populations as regards number of patients, proportion of alcoholics, and those with severe liver disease. Importantly, 17–65% of patients did not have a baseline and/or a repeat HVPG measurement, many because they rebled early (7–22%), limiting the clinical applicability of HVPG measurement. These groups are excluded from evaluation in those studies where the relationship between reduction of rebleeding and haemodynamic targets is strongest. This important source of bias, as well as other contrasting data, make it difficult to interpret the prognostic significance of haemodynamic data and to propose their routine clinical use. In conclusion, the clinical validity and applicability of monitoring for target HVPG reductions is not sufficiently proven by these studies and needs to be specifically evaluated in a prospective trial.

INTRODUCTION

Pharmacological therapy is the first choice treatment for the prevention of variceal rebleeding as it is equivalent but less costly than sclerotherapy and banding for both primary and secondary prophylaxis. In early studies, non-selective beta blockade dosage was empirical (that is, to the maximum tolerated by the patient or to reduction of the resting pulse rate to 55/min). However, the key issue is whether targeted reduction of portal pressure, which involves a baseline and a repeated hepatic venous pressure gradient measurement (HVPG), is necessary in routine clinical practice. It significantly adds to the cost of pharmacological therapy, it is not universally available, and several issues regarding its use are as yet not clear, despite it being recommended in two recent reviews. Moreover, the cost effectiveness of HVPG measurement has been questioned in primary prevention and, furthermore, HVPG is known to decrease with time even in some untreated patients. Despite a recent paper on tailoring of drug therapy, only some of the above issues have been considered.

THE KEY STUDIES

There have been five major studies and one smaller series published as a correspondence in the context of prevention of variceal rebleeding in which HVPG has been measured at baseline and at a subsequent time point (table 1). Their targeted end points were all the same following the first report. These were an absolute reduction in HVPG to 12 mm Hg or less, or a 20% reduction or more in HVPG from baseline, and the occurrence of rebleeding from varices.

The main data of these five studies are summarised in tables 1–3, with additional data from our own study. The study by Sacerdoti and colleagues included only 11 cirrhotic patients treated with nadolol. Haemodynamic response, defined as a decrease in HVPG of only >12%, was observed in 54% of patients at one month, of whom none rebled. Among non-responders, 80% had rebleeding, the same proportion as in 11 untreated cirrhotic patients who served as controls.

SIMILARITIES AND DIFFERENCES BETWEEN THE KEY STUDIES

Superficially all of these studies appear similar but there are some marked differences between them, making the haemodynamic data difficult

Abbreviations: HVPG, hepatic venous pressure gradient

See end of article for authors’ affiliations

Correspondence to: Professor A K Burroughs, Hepatobiliary Medicine and Liver Transplant Unit, Royal Free Hospital, Pond St, London NW3 2QG, UK; Andrew.Burroughs@royalfree.nhs.uk

Accepted for publication 22 August 2003
to interpret, and raising questions as to their use as valid therapeutic targets for pressure reduction (tables 1, 2).

Patients in whom no baseline HVPG measurement or remeasurement took place (table 2)

Not all patients had HVPG measured and/or remeasured, and therefore in this subgroup responder/non-responder status could not be assessed, varying from 65% in the study of Patch and colleagues5 to 17% in that of Feu and colleagues15. Importantly, the rebleeding rate among these patients varied from 17% to 44% to 64%. However, the situation is more complex than one would expect. In Feu’s study15 the rebleeding rate was higher than in the non-responder group, as was the case in Patch’s study,6 while in McCormick’s study7 it was approximately equivalent to the non-responder group. In the studies of Villanueva and colleagues,6,7 the rebleeding rate in patients in whom no repeat HVPG measurement took place was the same in both studies, being intermediate between the rebleeding rate in responders and non-responders in the first study— the expected outcome—but in the second study it was equivalent to the responders’ rebleeding rates. This represents an important source of bias.

Interval to remeasurement of HVPG

One reason why remeasurement could not take place is that some patients rebled before the second haemodynamic measurement: “some” (that is, no number specified) in the Villanueva papers,6 7% in Feu and colleagues,15 16% in McCormick and colleagues,17 and 22% in Patch and colleagues.6

“Clearly, if many patients rebled very early, it greatly diminishes the clinical applicability of remeasuring HVPG”

This raises an issue of when to remeasure HVPG,6 as the intervals to remeasurement (table 1) were 1–3 months,6 3 months,15 a mean of 5.3 months,16 and a mean of 57 days.6 Overall, between 25% and 44% of rebleeders rebled

Table 1  Key published studies of repeated hepatic venous pressure gradient (HVPG) measurement in the prevention of variceal rebleeding: total populations and haemodynamic responders (absolute numbers of patients in parentheses)

<table>
<thead>
<tr>
<th>Study</th>
<th>No of patients</th>
<th>% of responders</th>
<th>% of non-responders</th>
<th>Time to remeasurement</th>
<th>Remeasurement took place</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feu15</td>
<td>83</td>
<td>43%</td>
<td>57%</td>
<td>3–4</td>
<td>83 (69)</td>
</tr>
<tr>
<td>Villanueva6,7</td>
<td>43%</td>
<td>57%</td>
<td>125</td>
<td>4–6</td>
<td>43% (31)</td>
</tr>
<tr>
<td>McCormick17</td>
<td>63</td>
<td>37%</td>
<td>63%</td>
<td>4–6</td>
<td>63 (45)</td>
</tr>
<tr>
<td>Villanueva8</td>
<td>72%</td>
<td>28%</td>
<td>72</td>
<td>1–3</td>
<td>72% (72)</td>
</tr>
<tr>
<td>Patch4</td>
<td>51%</td>
<td>49%</td>
<td>51%</td>
<td>51</td>
<td>51% (51)</td>
</tr>
</tbody>
</table>

Table 2  Patients rebleding in the key study populations of repeated hepatic venous pressure gradient (HVPG) measurement in the pharmacological prevention of variceal rebleeding (absolute numbers in parentheses)

<table>
<thead>
<tr>
<th>Study</th>
<th>No of patients</th>
<th>HVPG not measured</th>
<th>HVPG not remeasured</th>
<th>Rebleeding not remeasured</th>
<th>Rebleeding (patient groups)</th>
<th>Haemodynamic responders</th>
<th>Haemodynamic non-responders</th>
<th>Repeat HVPG &lt;12 mm Hg</th>
<th>Rebleeding before remeasurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feu15</td>
<td>83</td>
<td>17% (14)</td>
<td>17% (14)</td>
<td>64% (9/14)</td>
<td>36% (25/69)</td>
<td>8% (2/25)</td>
<td>52% (23/44)</td>
<td>0% (0/6)</td>
<td>7% (5/69)</td>
</tr>
<tr>
<td>Villanueva6,7</td>
<td>43%</td>
<td>28% (12)</td>
<td>17% (12)</td>
<td>17% (2/12)</td>
<td>26% (11/43)</td>
<td>7% (1/14)</td>
<td>47% (8/17)</td>
<td>-% (0/0)</td>
<td>16% (7/44)</td>
</tr>
<tr>
<td>McCormick17</td>
<td>63</td>
<td>11% (7)</td>
<td>17% (11)</td>
<td>28% (5/18)</td>
<td>37% (16/44)</td>
<td>43% (12/28)</td>
<td>25% (4/16)</td>
<td>-% (0/0)</td>
<td>16% (7/44)</td>
</tr>
<tr>
<td>Villanueva8</td>
<td>72%</td>
<td>33% (23)</td>
<td>33% (23)</td>
<td>33% (4/23)</td>
<td>37% (24/72)</td>
<td>16% (4/25)</td>
<td>67% (16/24)</td>
<td>16% (7/44)</td>
<td>11% (1/9)</td>
</tr>
<tr>
<td>Patch4</td>
<td>51%</td>
<td>33% (23)</td>
<td>33% (23)</td>
<td>33% (11/33)</td>
<td>37% (19/51)</td>
<td>16% (4/25)</td>
<td>22% (2/9)</td>
<td>50% (1/2)</td>
<td>22% (5/23)</td>
</tr>
</tbody>
</table>

*Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm).
†Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm).
‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm).
§Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)).
*Calculation on the 44 included patients.
**Mean (range).
before remeasurement. Clearly, if many patients rebleed very early, it greatly diminishes the clinical applicability of remeasuring HVPG.

The proportion of haemodynamic responders in the drug arms of all studies varied between 36% and 64%. This variability could be influenced, and thus explained, by the time interval to the second HVPG measurement. The variability is not explained by the proportion of Child class C patients, although many may have rebled early, or by the baseline HVPG value or by mean drug dosage.

The lowest haemodynamic response rate was found by Feu and colleagues, perhaps because their patients did not receive nitrates. In McCormick’s study, which had the highest haemodynamic response rate, 68% of patients had nitrates added (although the mean nitrate dose was about half that used in the Villanueva studies), yet there was also the longest time interval to remeasurement.

**Rates of rebleeding**

The overall rebleeding rates in those patients in whom HVPG was remeasured were very similar in the four studies, varying between 33% and 37%, with the exception of the first Villanueva study which also used nitrates in which the rebleeding rate was 26%. These data are consistent with the second study, which also used nitrates, because if one excludes the 12 patients who did not receive nadolol throughout (eight of them subsequently rebled) the rebleeding rate was 27%. These lower rebleeding rates may be related to the shorter follow up in these two studies rather than to the baseline HVPG reported to be predictive of rebleeding while in the study by McCormick and colleagues in which HVPG was remeasured at a mean of 49 days to the second HVPG remeasurement. This could be due to the bias of exclusion of those patients who rebled before remeasurement.

There were lower rebleeding rates in non-responders in the studies with a higher percentage of alcoholic cirrhosis so that the relationship between responder status and rebleeding risk may be different in alcoholic cirrhosis compared with others. Abstinence may have a major influence on haemodynamic response and rebleeding rates, and conversely non-compliance may lead to more rebleeding. This may also explain the lack of relationship between haemodynamic response and rebleeding rates in McCormick’s study (with the highest prevalence of alcoholic cirrhosis). These issues have not been adequately assessed in all of the studies.

**Influence of baseline HVPG**

Interpretation of the prognostic value of baseline HVPG could be affected by excluding patients who rebled before remeasurement. This was not the case in the study by Patch and colleagues in which several patients who rebled did so before remeasurement but were not excluded from the evaluation of baseline HVPG. Indeed, only in this study was baseline HVPG reported to be predictive of rebleeding while the other studies did not specifically comment on this.

An interesting comparison can be made in the two papers by Villanueva and colleagues which were very similar with regard to the population studied, treatment given, schedule of haemodynamic measurements, and duration of follow up (table 1). The main difference between the studies was baseline HVPG, which was substantially higher in the second study (mean HVPG 19.9 (3.5) mm Hg) vs 17.7 (3.4) mm Hg). This probably explains the higher mortality (32% vs 9%) in this study. Indeed, there is an increase in mortality with increasing HVPG in many studies in hepatology, including a study in which HVPG was measured at two days after bleeding. The higher mean baseline HVPG could also be an explanation for drug treatment only reducing rebleeding rates in Child A patients in the second Villanueva study while rebleeding rates were similar in all Child classes in the first study. In this first study, Child B and Child C patients could have benefited because their baseline HVPG was already lower. Moreover, in the second Villanueva study, six patients randomised did not start nadolol therapy because of contraindications and were only given isosorbide mononitrate, and another six patients stopped nadolol (two due to complications and four due to non-compliance). Of these 12 patients, eight rebled, which means that at least two and perhaps all six patients who had contraindications to nadolol

| Table 3 Independent risk factors for variceal rebleeding in the key studies |
|------------------|------------------|------------------|------------------|------------------|
| Feu et al.       | Villanueva et al. | Patch et al.     |
| **Absence of haemodynamic response** | **Sclerotherapy vs v drug treatment** | **HVPG at baseline** |
| 145              | 15               | 17              |
| **Sclerotherapy v drug treatment** | **Endoscopic banding ligation v drug treatment** | **HVPG at 3rd month** |
| 51%              | 70%              | 22%             |
| **HVPG at 3rd month** | **Absence of haemodynamic response** | **Child-Pugh score at 3rd month** |
| 61%              | 64%              | 64%             |
| **Absence of haemodynamic response** | **Child-Pugh score at 3rd month** | **HVPG at baseline** |
| 61%              | 64%              | 64%             |

HVPG, hepatic venous pressure gradient.
rebleed. Clearly, an intention to treat analysis is correct statistically but in the clinical interpretation of rebleeding, patients who had contraindications to nadolol, and therefore never had the drug administered, cannot be considered failures of drug therapy. Because it was not stated whether the six patients who suspended nadolol did or did not have a second haemodynamic measurement, it is again difficult to interpret the relationship between rebleeding and haemodynamic measurement.

OTHER STUDIES
In some of these, the definition of haemodynamic response was not defined or the percentage of haemodynamic responders and non-responders was not reported, and thus cannot be evaluated.

‘Early measurement of HVPG after bleeding within 48 hours correlates with early rebleeding’

Early measurement of HVPG after bleeding within 48 hours correlates with early rebleeding. The prognostic value of a single HVPG measurement in patients with recent bleeding with respect to rebleeding has been assessed in five studies; threethree failed to show a correlation between HVPG and rebleeding in contrast with the other two. Differences in timing of HVPG measurement make it difficult to compare these studies directly, again underscoring the need for standardisation before the prognostic value of this technique can be considered valid.

The acute HVPG response to a single oral dose of propranolol did not predict rebleeding in 77 patients. A study of a single intravenous dose of propranolol (33 patients) did not report rebleeding in non-responders so that it is impossible to assess.

Two other studies have also considered the importance of haemodynamic monitoring for preventing variceal bleeding during drug therapy, but their study populations comprised combined groups with and without a history of prior variceal haemorrhage, and thus cannot be readily compared with the key studies discussed above. Indeed, there seems to be a difference in haemodynamic response in patients receiving pharmacological therapy for primary compared with secondary prevention of variceal bleeding, as well as very different risks of bleeding. In patients without varices, HVPG reduction after beta blockade is greater than that in those with varices. Populations of primary and secondary prevention should be kept apart when evaluating study results.

‘There seems to be a difference in haemodynamic response in patients receiving pharmacological therapy for primary compared with secondary prevention of variceal bleeding’

A recent study found that a lack of haemodynamic response during drug therapy for secondary prevention of variceal bleeding was associated not only with rebleeding but also with development of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy, as well as with a tendency to reduced survival, but it is unclear if there was a concomitant improvement in liver function.

Fewer data exist for monitoring target reduction of HVPG in primary prophylaxis. Merkel and colleagues found that variceal bleeding was significantly more likely in poor responders while there was no significant difference in baseline HVPG between bleeders and non-bleeders; none of the patients with a HVPG <12 mm Hg suffered a haemorrhage.

Groszmann and colleagues found that no patient who achieved a HVPG of <12 mm Hg during subsequent measurements experienced a haemorrhage. When propranolol was withdrawn, the risk of variceal haemorrhage returned to what would be expected in an untreated population so that lifelong therapy is needed.

PRECISION OF HVPG MEASUREMENT
A recent report comprising 102 patients suggested that HVPG measurement itself may not be as reliable as previously thought as 61% had a difference of between 4 and 34 mm Hg in HVPG measurement in two separate hepatic veins. If a 4 mm Hg difference in HVPG is considered, when baseline HVPG is 20 mm Hg, this already produces a 20% change. Thus defining a haemodynamic response by a percentage HVPG decrease of this magnitude, such as in this example, could be flawed due to the variability in measurement. However, in practice, the same hepatic vein is usually cannulated but nevertheless even when considering an intra-subject variation of 1–2 mm Hg, which is commonly acknowledged, this can make a difference in considering whether a patient is above or below 12 mm Hg or achieves a decrease of more or less than 20% from baseline. It is self-evident that it is much easier to achieve a 20% decrease, with a lower HVPG baseline value; the lower rebleeding rate in patients with a >20% decrease may indeed be correlated with a lower baseline HVPG value, as was the case in two of the studies.

DISCUSSION
Detailed evaluation of the key studies showed great heterogeneity in the data. In particular, the patient populations were different in the proportion of alcoholic patients and those with severe liver disease. Baseline HVPG and the interval to remeasurement were also very variable, which obviously can lead to different proportions of patients achieving the target reductions of >20% reduction in HVPG from baseline and <12 mm Hg absolute reduction. In addition, there is a spontaneous reduction in HVPG with time, particularly in alcoholics who abstain. The use of combination therapy, particularly nitrates, and perhaps spironolactone (not detailed in all studies, although ascitic patients are included), could affect the proportion of responders and rebleeders. The error in measurement may come into play, particularly if patients with lower pressures are being considered.

‘We view the current data as insufficient evidence to support monitoring the targeted reduction of HVPG in routine clinical practice’

Therefore, the haemodynamic targets themselves, whether or not achieved by combination therapy or whenever achieved in time from the index bleeding episode, cannot be considered robust and clinically applicable. We view the current data as insufficient evidence to support monitoring the targeted reduction of HVPG in routine clinical practice, as is now recommended.

Firstly, the bias introduced due to rebleeding before remeasurement of HVPG in some patients and failure to remeasure HVPG in all patients makes it very difficult to be certain of the haemodynamic thresholds.

The interval to remeasurement is of undeniable importance. The known reduction of HVPG with time after variceal bleeding makes it difficult to compare studies. Failure to achieve the haemodynamic target without rebleeding may be very relevant clinically. If after a long period the patient has not rebled, despite not achieving the haemodynamic targets, this may mean that for this particular patient
the likelihood of rebleeding is far less. This needs to be studied. It is possible that for the predictive assessment of pressure measurement in response to medical treatment for the prevention of variceal rebleeding, the baseline HVPG value could be of even greater importance than the haemodynamic response. The decrease in HVPG by ≥20% or to <12 mm Hg may be an expression of a lower baseline HVPG value. This could be especially true if those patients who rebleed early, and thus cannot have a remeasurement, have a higher baseline HVPG.

Combination therapy with nitrates increases the percentage of haemodynamic responders,6–8 as assessed by HVPG, but its increased therapeutic efficacy compared with a non-selective beta blocker on its own in randomised clinical trials remains of little clinical applicability.

Do haemodynamic targets have prognostic value? There is little doubt that if one considers cohorts of patients, HVPG is indeed correlated with the risk of variceal bleeding, and that theoretically, target reduction could be of some use in evaluating the response during drug therapy. However, the evidence for the 20% HVPG decrease from baseline as an appropriate target reduction seems to be of questionable value due to the biases illustrated in the studies. In contrast, decrease in HVPG to a value of 12 mm Hg does seem to be of prognostic significance in the majority of studies, but as it only identifies a small percentage of patients (12–48%, median 14%)6–15,17 it makes HVPG measurement and remeasurement of little clinical applicability.

“Logically, one should use target reduction in HVPG as a means of identifying patients who are less likely to bleed while complying with their given therapy”

Logically, one should use target reduction in HVPG as a means of identifying patients who are less likely to bleed while complying with their given therapy, and for those who do not achieve these targets, to offer them alternative therapy that will reduce their risk of rebleeding and improve survival. Ultimately, the only means of assessing the clinical utility of evaluating the haemodynamic response in patients given drug therapy for secondary prophylaxis of variceal bleeding would be a trial in which there would be four groups: one without HVPG measurement, and the other three groups in which HVPG measurements were performed. These three groups would be identified by randomisation at the second HVPG measurement so that haemodynamic non-responders would be randomised, either to continuation of drug therapy or to an alternative treatment such as endoscopic banding ligation with or without drugs. The remaining group would be the haemodynamic responders. In such a study an appropriate time interval which is clinically applicable for the repeat measurement would need to be defined a priori, perhaps as short as two weeks from the index bleeding episode.

Authors’ affiliations
U Thalheimer, M Mele, D Patch, A K Burroughs, Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, Pond St, London NW3 2GG, UK

REFERENCES

Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence
U Thalheimer, M Mela, D Patch and A K Burroughs

*Gut* 2004 53: 143-148
doi: 10.1136/gut.53.1.143